• On June 27, 2026, QuidelOrtho Corporation was removed from several Russell growth and small-cap benchmarks, including the Russell 2000 Growth, Russell 3000 Growth, Russell 3000E Growth, and Russell 2500 Growth indexes.
• A few days earlier, QuidelOrtho had also announced the upcoming appointment of experienced medical-technology finance executive Micah Young as Chief Financial Officer, signaling a leadership transition in its financial stewardship.
• Next, we’ll examine how QuidelOrtho’s removal from multiple Russell growth indexes may influence its investment narrative and risk profile.

Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

QuidelOrtho Investment Narrative Recap

To own QuidelOrtho today, you need to believe its broad diagnostics portfolio and international expansion can ultimately offset shrinking pandemic testing and portfolio exits, despite ongoing losses. The immediate catalyst is whether management can execute on cost savings and integration while stabilizing core revenues; removal from multiple Russell growth indexes may add some near term share price volatility but does not fundamentally change those execution and demand risks, which remain centered on post COVID normalization and product concentration.

The recent appointment of Micah Young as Chief Financial Officer is especially relevant here, given QuidelOrtho’s unprofitable status, high leverage, and need to fund integrations and new platforms. His prior experience in medical technology finance, capital allocation, and investor engagement could be important for how the company manages cost programs, investment in LEX Diagnostics, and balance sheet flexibility, all of which tie directly into whether the current catalysts can translate into a more sustainable earnings profile.

Yet despite these potential positives, investors should also be aware that...

QuidelOrtho's narrative projects $3.0 billion revenue and $393.9 million earnings by 2029. This requires 3.3% yearly revenue growth and an earnings increase of about $1.5 billion from -$1.1 billion today.

Uncover how QuidelOrtho's forecasts yield a $34.67 fair value, a 90% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming revenues could reach about US$3.1 billion and earnings around US$369.3 million by 2029, which is a much rosier path than the consensus narrative and may need to be revisited in light of both the index removal and the risk that reimbursement and procurement changes could pressure margins more than previously expected.

Explore 2 other fair value estimates on QuidelOrtho - why the stock might be worth just $34.67!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your QuidelOrtho research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free QuidelOrtho research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate QuidelOrtho's overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.